IDXG dividend history

Q4 and FY Revenue of $9.2 million and $38.7 millionQ4 and FY Income from Continuing Operations of $22.8 million and $25.0 million (benefiting from a one-time, non-cash tax-related accounting adjustment)Q4 and FY Thyroid volume year-over-year increase of 11% and 13%Q4 and FY Thyroid revenue year-over-year increase of 14% and 21% PARSIPPANY, NJ, March 30, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided a business and financial update. Q4 and FY revenue were $9.2 million and $38.7 million, respectively. Q4 and FY income from continuing

 ●Q1 Revenue of $10.4 million up 6% versus Prior Year ●Q1 Net Loss improved $2 million versus Prior Year ●Days Sales Outstanding (DSO) decreased by 27% PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the first quarter ended March 31, 2022 and provided a business and financial update. First quarter Net Revenue was $10.4 million, a 6% increase as compared to the same period of 2021. Our Net Loss in the first quarter of 2022 was $2.2 million, which represents an improvement of approximately $2 million from the prior year first quarter, driven by higher Net Revenues and lower oper

 ●Q3 Revenue of $9.5 Million is a 15% Improvement versus Q3 2020 ●Year to Date Revenue of $30.5 Million Up 34% Versus Prior Year ●Second Consecutive Record Cash Collection Quarter ●Significantly Improved Liquidity with Comerica Bank $7.5 Credit Facility ●Entered into $8 million term loan with BroadOak Fund, V, L.P. ●Announcing New Proposed $30 Million Rights Offering PARSIPPANY, NJ, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the fiscal quarter ended September 30, 2021 and provided a business and financial update. "2021 has been a dynamic and meaningful year in the evolution of Interpace

 ●Q2 Revenue of $11.2 Million Surpasses Q1 2021 as Company's Highest Revenue Quarter  ●Company approaching EBITDA breakeven on Higher Clinical Volume, Revenue, Improved Gross Profit and Operating Expense Containment ●Restructuring Exceeding Full-Year Savings Expectations ●On Track to Exceed Full Year 2021 Revenue Growth of 35% ●Q2 Cash Collections in Excess of $11 Million Representing Highest Collection Quarter PARSIPPANY, NJ, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the fiscal quarter ended June 30, 2021 and provided a business and financial update. "Followin

 ● Q1 Revenue of $9.8 Million is Company's Highest as Combined Molecular Diagnostics and Pharma Services Business  ● Q2 Revenue Expected to Exceed $11 million  ● On Track to Exceed Full Year 2021 Revenue Growth of 35%  ●Moving Up Target For EBITDA Breakeven from Q4 2021 to Q3 2021 PARSIPPANY, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the fiscal quarter ended March 31, 2021 and provided a business and financial update. "We are very pleased with our first quarter operating results which are on track and in accordance with our growth, restructuring and reprioritization p

Third Quarter Net Revenue of $8.2 Million Up 7% vs Prior Year; Third Quarter Year to Date Net Revenue of $22.8 Million Up 14% vs Prior YearEstimates Fourth Quarter Net Revenue range of $9.0 million - $10.0 millionRealized Reimbursement on Higher ThyGeNEXT Pricing in JanuaryClosed $5 Million Bridge Loan Agreement with Existing Private Equity Investors and terminated the SVB credit facilityCash balance as of January 15, 2021 was $6.1 million net of restricted cash Conference Call and Webcast Thursday January 21, 2021 at 4:30 pm ET PARSIPPANY, NJ, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (Nasdaq: IDXG) today announced financial res